A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Recruiting

Treg TherapeuticA Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Sponsor:

Sonoma Biotherapeutics, Inc.

Code:

NCT07123038

Conditions

Rheumatoid Arthritis (RA)

Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Long Term Safety Monitoring Procedures

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-13. This information was provided to ClinicalTrials.gov by Sonoma Biotherapeutics, Inc. on 2025-08-14.